F
Francis J. Giles
Researcher at National University of Ireland, Galway
Publications - 685
Citations - 42157
Francis J. Giles is an academic researcher from National University of Ireland, Galway. The author has contributed to research in topics: Imatinib mesylate & Myeloid leukemia. The author has an hindex of 105, co-authored 673 publications receiving 39961 citations. Previous affiliations of Francis J. Giles include University of Texas Health Science Center at Houston & University of Arkansas for Medical Sciences.
Papers
More filters
Journal ArticleDOI
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Hagop M. Kantarjian,Francis J. Giles,Lydia Wunderle,Kapil N. Bhalla,Susan O'Brien,Barbara Wassmann,Chiaki Tanaka,Paul W. Manley,Patricia Rae,William Mietlowski,Kathy Bochinski,Andreas Hochhaus,James D. Griffin,Dieter Hoelzer,Maher Albitar,Margaret Dugan,Jorge E. Cortes,Leila Alland,Oliver G. Ottmann +18 more
TL;DR: Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes.
Journal ArticleDOI
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
Michael J. Keating,Susan O'Brien,Maher Albitar,Susan Lerner,William Plunkett,Francis J. Giles,Michael Andreeff,Jorge E. Cortes,Stefan Faderl,Deborah A. Thomas,Charles Koller,William G. Wierda,Michelle A. Detry,Alice Lynn,Hagop M. Kantarjian +14 more
TL;DR: FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
Journal ArticleDOI
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Jean Pierre J. Issa,Guillermo Garcia-Manero,Francis J. Giles,Rajan Mannari,Deborah A. Thomas,Stefan Faderl,Emel Bayar,John Lyons,Craig S. Rosenfeld,Jorge E. Cortes,Hagop M. Kantarjian +10 more
TL;DR: It is concluded that decitabine is effective in myeloid malignancies, and low doses are as or more effective than higher doses.
Journal ArticleDOI
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian,Francis J. Giles,Norbert Gattermann,Kapil N. Bhalla,Giuliana Alimena,Francesca Palandri,Gert J. Ossenkoppele,Franck E. Nicolini,Stephen G. O'Brien,Mark R. Litzow,Ravi Bhatia,Francisco Cervantes,Ariful Haque,Yaping Shou,Debra Resta,Aaron Weitzman,Andreas Hochhaus,Philipp le Coutre +17 more
TL;DR: Nilotinib is highly active and safe in patients with CML-CP after imatinib failure or intolerance and was effective in patients harboring BCR-ABL mutations associated with imatinIB resistance (except T315I), and also in Patients with a resistance mechanism independent of B CR-ABl mutations.
Journal ArticleDOI
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Hagop M. Kantarjian,Yasuhiro Oki,Guillermo Garcia-Manero,Xuelin Huang,Susan O'Brien,Jorge E. Cortes,Stefan Faderl,Carlos E. Bueso-Ramos,Farhad Ravandi,Zeev Estrov,Alessandra Ferrajoli,William G. Wierda,Jianqin Shan,Jan Davis,Francis J. Giles,Hussain I. Saba,Jean Pierre J. Issa +16 more
TL;DR: It is concluded that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.